Jeffrey Zeitung, MD
Urology · la Jolla, CANPI 1366416851
Payments from drug & device makers
Across 155 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$761
- Urogen Pharma, Inc.$439
- EDAP Technomed Inc$339
- Coloplast$265
- Johnson & Johnson$231
- Immunitybio, Inc.$190
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,782100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $761 |
| Urogen Pharma, Inc. | 13 | $439 |
| EDAP Technomed Inc | 3 | $339 |
| Coloplast | 18 | $265 |
| Johnson & Johnson | 11 | $231 |
| Immunitybio, Inc. | 8 | $190 |
| Boston Scientific | 7 | $154 |
| Pfizer | 8 | $143 |
| Procept Biorobotics Corporation | 1 | $106 |
| Teleflex LLC | 3 | $91 |
| Endo Pharmaceuticals Inc. | 4 | $82 |
| Antares Pharma, Inc. | 3 | $63 |
| Astellas Pharma US Inc | 3 | $63 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| Ferring Pharmaceuticals Inc. | 3 | $61 |
| Neotract Inc. | 3 | $60 |
| Aytu Biopharma, Inc. | 3 | $55 |
| Blue Earth Diagnostics | 1 | $44 |
| Bayer | 3 | $44 |
| Urovant Sciences Inc | 2 | $43 |
| Seagen Inc. | 2 | $42 |
| Sun Pharmaceutical Industries Inc. | 1 | $37 |
| Histosonics, Inc. | 1 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $36 |
| Dendreon Pharmaceuticals LLC | 2 | $35 |
| AstraZeneca | 2 | $34 |
| Merck | 1 | $34 |
| Amgen | 1 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $28 |
| ABC Home Medical Supply, Inc. | 1 | $24 |
| Accord Healthcare, Inc. | 1 | $24 |
| Endo USA, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $20 |
| 180 Medical, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Duchesnay USA Incorporated | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Rochester Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AQUABEAM SYSTEM$106
How this compares
$3,782 in reported general payments places this provider in the 55th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 53 | $54,326 |
| GemtesaVibegron | 64 | $47,388 |
| Tamsulosin Hcl | 814 | $15,870 |
| Tadalafil | 169 | $11,730 |
| Finasteride | 764 | $11,728 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 524 | $10,397 |
| Silodosin | 133 | $9,251 |
| Testosterone | 62 | $8,367 |
| Solifenacin Succinate | 103 | $4,539 |
| Methenamine Hippurate | 53 | $4,373 |
| Dutasteride | 84 | $4,135 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,875 |
| Desmopressin Acetate | 75 | $2,224 |
| Tolterodine Tartrate ErTolterodine Tartrate | 39 | $2,192 |
| Oxybutynin Chloride ErOxybutynin Chloride | 83 | $2,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $63 | $54,32653 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $62 | $47,38864 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,324 urology providers in California.
Other urology in la Jolla
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.